🇺🇸 FDA
Patent

US 12070472

Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds

granted A61KA61K31/7076A61K31/7105

Quick answer

US patent 12070472 (Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds) held by The Board of Regents of the University of Texas System expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/7076, A61K31/7105, A61K45/06, A61K9/0019